



28 Disember 2017
28 December 2017
P.U. (A) 426

WARTA KERAJAAN PERSEKUTUAN

*FEDERAL GOVERNMENT
GAZETTE*

PERINTAH RACUN (PINDAAN JADUAL KETIGA)
(NO. 2)2017

*POISONS (AMENDMENT OF THIRD SCHEDULE)
(NO. 2) ORDER 2017*

DISIARKAN OLEH/
PUBLISHED BY
JABATAN PEGUAM NEGARA/
ATTORNEY GENERAL'S CHAMBERS

AKTA RACUN 1952

PERINTAH RACUN (PINDAAN JADUAL KETIGA) (NO. 2) 2017

PADA menjalankan kuasa yang diberikan oleh subseksyen 30(2) Akta Racun 1952 [*Akta 366*], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut:

Nama

1. Perintah ini bolehlah dinamakan **Perintah Racun (Pindaan Jadual Ketiga) (No. 2) 2017**.

Pindaan Jadual Ketiga

2. Jadual Ketiga kepada Akta Racun 1952 dipinda—

(a) dalam perenggan 1—

- (i) dengan memasukkan sebelum butiran “Amfepramone” butiran yang berikut:

“N-(Adamantan-1-yl)-1-pentyl-1H-indazole-3-carboxamide
(APINACA)
N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-
carboxamide (5F-APINACA)”;

- (ii) dengan memasukkan selepas butiran “Amfepramone” butiran yang berikut:

“N- [(1S) - 1- (Aminocarbonyl) - 2- methylpropyl] - 1-
(cyclohexylmethyl) 1H- indazole- 3- carboxamide
(AB-CHMINACA)”;

- (iii) dengan memasukkan selepas butiran “Clotiazepam” butiran yang berikut:

“N-{{1-(Cyclohexylmethyl)-1H-indol-3yl}carbonyl}-3-methyl-L-valinate (MDMB-CHMICA)”;

- (iv) dengan memasukkan selepas butiran “Ethylamphetamine” butiran yang berikut:

“Ethylone (3,4-Methylenedioxy-N-ethylcathinone) Ethylphenidate”;

- (v) dengan memasukkan selepas butiran “[1-(5-fluoropentyl)-1H-indol-3-yl](naphthalen-1-yl) methanone (AM-2201)” butiran yang berikut:

“[1-(5-fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl) methanone (XLR-11)”;

- (vi) dengan memasukkan selepas butiran “Methaqualone” butiran yang berikut:

“Methiopropamine (MPA)
Methoxetamine (MXE)”;

- (vii) dengan memasukkan selepas butiran “3,4-Methylenedioxypyrovalerone (MDPV)” butiran yang berikut:

“4-Methylethcathinone (4-MEC)
Methyl 2-({[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl}amino)-3-methylbutanoate (5F-AMB)
3-Methylmethcathinone (3-MMC)”;

- (viii) dengan memasukkan selepas butiran “Naphtalen-1-yl-(1-pentyl-1H-indol-3-yl)methanone (JWH-018)” butiran yang berikut:

“Para-methyl-4-methylaminorex (4,4'-DMAR)”;

- (ix) dengan memasukkan selepas butiran “Pentazocine” butiran yang berikut:

“Pentedrone (α -methylaminovalerophenone)”;

- (x) dengan memasukkan selepas butiran “Pyrovalerone” butiran yang berikut:

“ α -Pyrrolidinovalerophenone (α -PVP)
Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate (5F-PB-22)”;

- (b) dalam perenggan 2, dengan memasukkan selepas butiran “Pethidine” butiran yang berikut:

“Remifentanil”.

Dibuat 15 November 2017
[KKM.R.600-1/1/56; PN(PU2)172/XV]

DATUK SERI DR. S. SUBRAMANIAM
Menteri Kesihatan

POISONS ACT 1952

POISONS (AMENDMENT OF THIRD SCHEDULE) (NO. 2) ORDER 2017

IN exercise of the powers conferred by subsection 30(2) of the Poisons Act 1952 [Act 366], the Minister, after consultation with the Poisons Board, makes the following order:

Citation

1. This order may be cited as the **Poisons (Amendment of Third Schedule) (No. 2) Order 2017**.

Amendment of Third Schedule

2. The Third Schedule to the Poisons Act 1952 is amended—

(a) in paragraph 1—

- (i) by inserting before the item “Amfepramone” the following items:

“N-(Adamantan-1-yl)-1-pentyl-1H-indazole-3-carboxamide
(APINACA)

N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-
carboxamide (5F-APINACA)”;

- (ii) by inserting after the item “Amfepramone” the following item:

“N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-
(cyclohexylmethyl) 1H-indazole-3-carboxamide (AB-
CHMINACA)”;

- (iii) by inserting after the item “Clotiazepam” the following item:

“N-{{1-(Cyclohexylmethyl)-1H-indol-3yl}carbonyl}-
3-methyl-L-valinate (MDMB-CHMICA)”;

- (iv) by inserting after the item “Ethylamphetamine” the following items:

“Ethylone (3,4-Methylenedioxy-N-ethylcathinone)
Ethylphenidate”;

- (v) by inserting after the item “[1-(5-fluoropentyl)-1H-indol-3-yl](naphthalen-1-yl) methanone (AM-2201)” the following item:

“[1-(5-fluoropentyl)-1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl) methanone (XLR-11)”;

- (vi) by inserting after the item “Methaqualone” the following items:

“Methiopropamine (MPA)
Methoxetamine (MXE)”;

- (vii) by inserting after the item “3,4-Methylenedioxyprovalerone (MDPV)” the following items:

“4-Methylethcathinone (4-MEC)
Methyl 2-({[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl}amino)-3-methylbutanoate (5F-AMB)
3-Methylmethcathinone (3-MMC)”;

- (viii) by inserting after the item “Naphtalen-1-yl-(1-pentyl-1H-indol-3-yl)methanone (JWH-018)” the following item:

“Para-methyl-4-methylaminorex (4,4'-DMAR)”;

(ix) by inserting after the item “Pentazocine” the following item:

“Pentedrone (α -methylaminovalerophenone)”; and

(x) by inserting after the item “Pyrovalerone” the following items:

“ α -Pyrrolidinovalerophenone (α -PVP)

Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate (5F-PB-22)”; and

(b) in paragraph 2, by inserting after the item “Pethidine” the following item:

“Remifentanil”.

Made 15 November 2017

[KKM.R.600-1/1/56; PN(PU2)172/XV]

DATUK SERI DR. S. SUBRAMANIAM
Minister of Health